Humacyte Presents Long-Term Data on Symvess at VESS Annual Meeting
Humacyte announced the presentation of long-term data assessing the durability of Symvess in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society, VESS, in Olympic Valley, CA. The presentation, titled "Long-Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial." In the V005 trial, Symvess maintained long-term structural integrity, exhibited low infection rates, and supported high rates of limb salvage in patients who were followed for up to 36 months. Among those treated in the V005 Phase 2/3 study were 54 patients who underwent extremity vascular repair with Symvess for whom treatment with autologous vein, the standard of care, was not feasible. Within this patient population, once early complications from the traumatic injuries resolved, the rates of conduit infection, limb salvage, and patient survival plateaued and remained relatively constant through the three years of follow-up. Symvess maintained an infection-free rate of 92.9% from months 3-36, with no infections after day 37 and only three conduit infections overall. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months, despite a severely injured trauma cohort.
